The HORIZON-HLTH-2022-STAYHLTH-02/101095679 project entitled: “Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH transition to inform early prevention and treatment strategies” has been funded with over 6 million € in which 15 European institutions and 3 UK partners participate under the coordination of Prof. Javier Cubero (UCM) with the aim to identify biomarkers for early detection of chronic inflammation in patients with non-alcoholic steatohepatitis (NASH).
The group “Mitochondrial regulation of Cell Death“ of the IIBB will lead the in vivo modeling of health-disease transtions in humanized mice as part of WP3. The use of humanized FRGN/STARD1 mice, in which >80% of murine hepatocytes are replaced with human hepatocytes overexpressing STARD1, a mitochondrial cholesterol transporter, reproduces the phenotype of human NASH and represents a unique model to test the impact of therapies targeting chronic inflammation and the sensitization of NASH development towards drug-induced liver injury.
